BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

773 related articles for article (PubMed ID: 24433507)

  • 1. Novel treatment of acute promyelocytic leukemia: As₂O₃, retinoic acid and retinoid pharmacology.
    Zhu G
    Curr Pharm Biotechnol; 2013; 14(9):849-58. PubMed ID: 24433507
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Uncoupling RARA transcriptional activation and degradation clarifies the bases for APL response to therapies.
    Ablain J; Leiva M; Peres L; Fonsart J; Anthony E; de Thé H
    J Exp Med; 2013 Apr; 210(4):647-53. PubMed ID: 23509325
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Autophagy contributes to therapy-induced degradation of the PML/RARA oncoprotein.
    Isakson P; Bjørås M; Bøe SO; Simonsen A
    Blood; 2010 Sep; 116(13):2324-31. PubMed ID: 20574048
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Activation of a promyelocytic leukemia-tumor protein 53 axis underlies acute promyelocytic leukemia cure.
    Ablain J; Rice K; Soilihi H; de Reynies A; Minucci S; de Thé H
    Nat Med; 2014 Feb; 20(2):167-74. PubMed ID: 24412926
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missense mutations in PML-RARA are critical for the lack of responsiveness to arsenic trioxide treatment.
    Goto E; Tomita A; Hayakawa F; Atsumi A; Kiyoi H; Naoe T
    Blood; 2011 Aug; 118(6):1600-9. PubMed ID: 21613260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Distinct interactions of PML-RARalpha and PLZF-RARalpha with co-repressors determine differential responses to RA in APL.
    He LZ; Guidez F; Tribioli C; Peruzzi D; Ruthardt M; Zelent A; Pandolfi PP
    Nat Genet; 1998 Feb; 18(2):126-35. PubMed ID: 9462740
    [TBL] [Abstract][Full Text] [Related]  

  • 7. PML-RARA-RXR oligomers mediate retinoid and rexinoid/cAMP cross-talk in acute promyelocytic leukemia cell differentiation.
    Kamashev D; Vitoux D; De Thé H
    J Exp Med; 2004 Apr; 199(8):1163-74. PubMed ID: 15096541
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Eradication of acute promyelocytic leukemia-initiating cells by PML/RARA-targeting.
    Nasr R; de Thé H
    Int J Hematol; 2010 Jun; 91(5):742-7. PubMed ID: 20455087
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Mutations affecting both the rearranged and the unrearranged PML alleles in refractory acute promyelocytic leukaemia.
    Iaccarino L; Ottone T; Divona M; Cicconi L; Cairoli R; Voso MT; Lo-Coco F
    Br J Haematol; 2016 Mar; 172(6):909-13. PubMed ID: 26728337
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Autophagic degradation of an oncoprotein.
    Bøe SO; Simonsen A
    Autophagy; 2010 Oct; 6(7):964-5. PubMed ID: 20724820
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Accelerated degradation of PML-retinoic acid receptor alpha (PML-RARA) oncoprotein by all-trans-retinoic acid in acute promyelocytic leukemia: possible role of the proteasome pathway.
    Yoshida H; Kitamura K; Tanaka K; Omura S; Miyazaki T; Hachiya T; Ohno R; Naoe T
    Cancer Res; 1996 Jul; 56(13):2945-8. PubMed ID: 8674046
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Retinoic acid regulatory pathways, chromosomal translocations, and acute promyelocytic leukemia.
    Chen Z; Tong JH; Dong S; Zhu J; Wang ZY; Chen SJ
    Genes Chromosomes Cancer; 1996 Mar; 15(3):147-56. PubMed ID: 8721678
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The arsenic-based cure of acute promyelocytic leukemia promotes cytoplasmic sequestration of PML and PML/RARA through inhibition of PML body recycling.
    Lång E; Grudic A; Pankiv S; Bruserud O; Simonsen A; Bjerkvig R; Bjørås M; Bøe SO
    Blood; 2012 Jul; 120(4):847-57. PubMed ID: 22692509
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Curing APL through PML/RARA degradation by As2O3.
    Lallemand-Breitenbach V; Zhu J; Chen Z; de Thé H
    Trends Mol Med; 2012 Jan; 18(1):36-42. PubMed ID: 22056243
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Fusion proteins of the retinoic acid receptor-alpha recruit histone deacetylase in promyelocytic leukaemia.
    Grignani F; De Matteis S; Nervi C; Tomassoni L; Gelmetti V; Cioce M; Fanelli M; Ruthardt M; Ferrara FF; Zamir I; Seiser C; Grignani F; Lazar MA; Minucci S; Pelicci PG
    Nature; 1998 Feb; 391(6669):815-8. PubMed ID: 9486655
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In acute promyelocytic leukemia NB4 cells, the synthetic retinoid CD437 induces contemporaneously apoptosis, a caspase-3-mediated degradation of PML/RARalpha protein and the PML retargeting on PML-nuclear bodies.
    Giannì M; de Thé H
    Leukemia; 1999 May; 13(5):739-49. PubMed ID: 10374879
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Interstitial insertion of retinoic acid receptor-alpha gene in acute promyelocytic leukemia with normal chromosomes 15 and 17.
    Hiorns LR; Min T; Swansbury GJ; Zelent A; Dyer MJ; Catovsky D
    Blood; 1994 May; 83(10):2946-51. PubMed ID: 8180390
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of t(15;17) chromosomal breakpoint sequences in therapy-related versus de novo acute promyelocytic leukemia: association of DNA breaks with specific DNA motifs at PML and RARA loci.
    Hasan SK; Ottone T; Schlenk RF; Xiao Y; Wiemels JL; Mitra ME; Bernasconi P; Di Raimondo F; Stanghellini MT; Marco P; Mays AN; Döhner H; Sanz MA; Amadori S; Grimwade D; Lo-Coco F
    Genes Chromosomes Cancer; 2010 Aug; 49(8):726-32. PubMed ID: 20544846
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clearance of PML/RARA-bound promoters suffice to initiate APL differentiation.
    Vitaliano-Prunier A; Halftermeyer J; Ablain J; de Reynies A; Peres L; Le Bras M; Metzger D; de Thé H
    Blood; 2014 Dec; 124(25):3772-80. PubMed ID: 25258343
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The molecular biology of acute promyelocytic leukemia.
    Slack JL; Gallagher RE
    Cancer Treat Res; 1999; 99():75-124. PubMed ID: 9891864
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 39.